EUVIMEDUpptäck EUVIMED
CrossrefInfokort

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue

Laura Connelly‐Smith, Caroline R. Alquist, Nicole A. Aqui, Jan C. Hofmann, Reinhard Klingel, Oluwatoyosi A. Onwuemene, Christopher J. Patriquin, Huy P. Pham, Amber P. Sanchez, Jennifer Schneiderman, Volker Witt, Nicole D. Zantek, Nancy M. Dunbar

Journal of Clinical Apheresis · 2023-04 · 38 (2) · 77-278

DOI: 10.1002/jca.22043 ↗
AbstractBibliografiska uppgifter

Abstract

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA) Special Issue Writing Committee is charged with reviewing, updating, and categorizing indications for the evidence‐based use of therapeutic apheresis (TA) in human disease. In the Ninth Edition, the JCA Special Issue Writing Committee has incorporated systematic review and evidence‐based approaches in the grading of evidence and categorization of apheresis indications to make recommendations on the use of apheresis in a wide variety of diseases and conditions. This edition has largely maintained the general layout and concept of a fact sheet introduced in the Fourth Edition (2007). Each fact sheet succinctly summarizes the evidence for the use of TA in a specific disease or medical condition. The Ninth Edition of the JCA Special Issue comprises 91 fact sheets and 166 graded and categorized indications. This includes seven new fact sheets, nine new indications on existing fact sheets, and eight changes in the category for existing indications. The Ninth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.

Kunskap som passar ditt arbete.

Från en kostnadsfri start via personlig litteratursökning till hela Research Suite.

Visa priser →

Ingår alla förlagsfulltexter?

Nej. Bibliografiska poster, abstrakt och fulltexter är olika typer av innehåll. Om en fulltext är tillgänglig beror på källan, Open Access och dina befintliga licenser. En EUVIMED-plan ersätter inga ytterligare förlagsrättigheter.

Visa priser →